.png){kind=icon}
返回
Modelling, gene expression mapping and post-mapping image analysis in the developing human brain
.png){kind=icon}
PRE
AI
DOI：10.1016/j.brainresbull.2005.05.022.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
As human brain development proceeds, there are complex changes in size and shape, most notably in the developing forebrain. Molecular technologies enable us to characterise the gene expression patterns that underlie these changes. To interpret these patterns the location of expression must be identified and, often, gene expression patterns compared for several genes or across several developmental stages. To facilitate interpretation we have generated a set of three-dimensional models using a recently developed technique, optical projection tomography. The models act as a framework onto which gene expression patterns are mapped and anatomical domains identified using custom-designed software, MAPaint. Here, we demonstrate their use to compare forebrain development at two embryonic stages (Carnegie stages 18 and 21; 44 and 52 days post conception, respectively) and as a means of recording, storing and visualising gene expression data for three example genes EMX1, EMX2 and OTX2. Anatomical domains were also mapped to the models and the comparison of gene expression and anatomical data is demonstrated at Carnegie stage 21. The three-dimensional models and sophisticated software facilitate the analysis and visualisation of morphological changes and gene expression patterns during early brain development and can be applied to the development of other complex structures. (c) 2005 Elsevier Inc. All rights reserved.
Keyword:
mammalian CNS
telencephalon
forebrain development
anatomical domains
optical projection tomography (OPT)
human
期刊
IF:
3.7
论文数:
7.0K
被引数:
1.2W
机构
暂无机构信息
引用论文
Forebrain gene expression domains and the evolving prosomeric model.png)
TRENDS IN NEUROSCIENCES
TRENDS IN NEUROSCIENCESIF15.1
PREAI
分享收藏A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy AdultsPLOS ONE
OAAI
PLOS ONEIF0
OAAI分享收藏 没有更多内容
没有更多内容